Last reviewed · How we verify
NCT04412811: CYTOALLOSURVEY
Prospective Survey of CMV, Herpesviruses Infections and Diseases in Allo-HSCT
trial in Hematologic Diseases in 1,310 participants. Completed in 31 March 2023.
31 July 2022
Quick facts
| Lead sponsor | Gruppo Italiano Trapianto di Midollo Osseo |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,310 |
| Start date | 1 January 2021 |
| Primary completion | 31 July 2022 |
| Estimated completion | 31 March 2023 |
| Sites | 50 locations across Italy |
Conditions studied
- Hematologic Diseases — all drugs for Hematologic Diseases →
- Stem Cell Transplant Complications — all drugs for Stem Cell Transplant Complications →
- Cytomegalovirus Viremia — all drugs for Cytomegalovirus Viremia →
- Herpesvirus Infection — all drugs for Herpesvirus Infection →
Sponsor
Gruppo Italiano Trapianto di Midollo Osseo — full company profile →
Who can join
Eligibility, any sex, with Hematologic Diseases or Stem Cell Transplant Complications. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Prospective observational study of epidemiological surveillance, multicenter, non-profit, spontaneous, Italian with objective to describe the incidence of CMV infections and diseases in adult and pediatric patients undergoing allo-HSCT during the first 6 months from transplant. This study will evaluate approximately 1500 subjects (with competitive enrolment) from GITMO investigational centers.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The Changing Impact of Human Cytomegalovirus Serology and Infection on Patient Outcome After Allogeneic Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey in the Era of Letermovir Prophylaxis.
Girmenia C, Chiusolo P, Marsili G, Piciocchi A, et al · · 2025 · cited 2× · PMID 40322267 · DOI 10.1093/ofid/ofaf233
Verify or expand the search:
- PubMed search for NCT04412811
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hematologic Diseases
Currently open trials in the same condition.
- NCT07257640 — IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia · Phase 1 · recruiting
- NCT06487247 — HEME Home Transfusion Program · NA · recruiting
- NCT05414045 — Autologous Testicular Tissue Transplantation · NA · recruiting
- NCT06613425 — Clinical Study of Combined Platelet Transfusion · Phase 4 · recruiting
- NCT06271252 — A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study · Phase 1 · recruiting
Other Gruppo Italiano Trapianto di Midollo Osseo trials
Trials by the same sponsor.
- NCT06790680 — GITMO AML/MDS-Relapse Registry Study · completed
- NCT04506320 — Novel Drugs After Allo-HSCT in Patients With Multiple Myeloma · completed
- NCT03270748 — Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies · Phase 2 · completed
- NCT04476199 — Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT · Phase 2 · active not recruiting
- NCT03494959 — Pentaglobin in CRE and PA Neutropenic Infections · Phase 2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04412811 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gruppo Italiano Trapianto di Midollo Osseo
- Last refreshed: 6 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04412811.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing